Palvella Therapeutics Inc (PVLA)

$PVLA up the Roger unTIL at least if no faaatch 💣 lands during 🐒🍌🧠⏰♾️

$PVLA still holding this 😊👌😎 target price $56

Truist Securities has adjusted their stance on Palvella Therapeutics ( $PVLA ), setting the rating to Buy with a target price of 56.

$PVLA Palvella Therapeutics added to Russell 3000, Russell 2000 Indexes Palvella Therapeutics announced it has been added to the broad-market Russell 3000 Index and the Russell 2000 Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution.

Canaccord Genuity has adjusted their stance on Palvella Therapeutics ( $PVLA ), setting the rating to Buy with a target price of 53 → 52.

$PVLA Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

HC Wainwright & Co. has updated their rating for Palvella Therapeutics ( $PVLA ) to Buy with a price target of 38.

$EDBL $LFCR $PVLA $SOND $VERO

WATCHLIST APR 14 2025. $AMGN Amgen Announced Global Phase 3 DeLLphi-304 Clinical Trial Evaluating IMDELLTRA As Treatment For Patients With Small Cell Lung Cance Met Its Primary Endpoint $OPTT Ocean Power Technologies shares are trading higher after the company announced it has signed a reseller agreement with Elektron. $IPA ImmunoPrecise Antibodies Announces Its Support For FDA's Recent Decision To Phase Out Animal Testing Requirements For Monoclonal Antibodies And Other Pharmaceutical Products $OBDC Jefferies Initiates Coverage On Blue Owl Capital with Buy Rating, Announces Price Target of $16 $PVLA Palvella Therapeutics' QTORIN Rapamycin For Microcystic LMs Treatment Featured By Dr. Amy Paller In Oral Presentation At 15Th World Congress Of Pediatric Dermatology In Buenos Aires, Argentina

$PVLA Palvella Therapeutics announces data on QTORIN rapamycin Palvella Therapeutics announced QTORIN rapamycin 3.9% anhydrous gel for the treatment of microcystic lymphatic malformations was featured by Dr. Amy Paller in an oral presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina. The oral presentation titled, "SELVA: A Phase 3 study with a fit-for-purpose primary endpoint evaluating QTORIN(TM) 3.9% rapamycin anhydrous gel in the treatment of microcystic lymphatic malformations in patients 3 years of age and older," highlighted: Microcystic LMs are congenital mosaic lesions that gradually increase in size with risk of complications and are best managed aggressively during childhood; Microcystic LMs are proliferative with no spontaneous regression; QTORIN rapamycin, an investigational therapy designed to selectively inhibit the mammalian target of rapamycin in the skin; A multicenter, open-label, 12-week, Phase 2 study evaluating the safety and efficacy of QTORIN rapamycin for microcystic LMs demonstrated: 100% of participants were either "Very Much Improved" or "Much Improved as rated by the Clinician Global Impression of Change, a 7-point change scale conducted by live clinician assessment; 83% of participants were either "Very Much Improved" or "Much Improved" as rated by the Patient Global Impression of Change, a 7-point change scale reported by patients; QTORIN rapamycin was generally well-tolerated; all treatment related adverse events were moderate or mild and there were no discontinuations due to adverse events.